PRA-va-sta-tin 
Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: hmg coa reductase inhibitors (statins)
Absorption: Poorly and variably absorbed following oral administration.
Distribution: Unknown.
Metabolism/Excretion: Extensively metabolized by the liver, most during first pass; excreted in bile and feces. 20% excreted unchanged by the kidneys.
Half-life: 1.3–2.7 hr.
Contraindicated in:
Use Cautiously in:
CNS: amnesia, confusion, dizziness, headache, insomnia, memory loss, weakness.
EENT: rhinitis.
Resp: bronchitis.
CV: chest pain, peripheral edema.
GI: abdominal cramps, constipation, diarrhea, flatus, heartburn, altered taste, drug-induced hepatitis, dyspepsia, ↑ liver enzymes, nausea, pancreatitis.
GU: erectile dysfunction.
Derm: rash, pruritus.
Endo: hyperglycemia.
MS: RHABDOMYOLYSIS, arthralgia, arthritis, immune-mediated necrotizing myopathy, myalgia, myositis.
Misc: hypersensitivity reactions.
Drug-Drug:
1 hr before or 4 hr after bile acid sequestrants.Renal Impairment
NDC Code*